7081-40-5
7081-40-5
Chemical Structure
Metixene hydrochloride hydrate
- CAS No.: 7081-40-5
- Formula:C20H26ClNOS
- Molecular Weight:363.94
IUPAC Name: 3-((9H-thioxanthen-9-yl)methyl)-1-methylpiperidine hydrochloride hydrate
InChIKey: RAOHHYUBMJLHNC-UHFFFAOYSA-N
SMILES: CN1CC(CCC1)CC2C3=C(C=CC=C3)SC4=C2C=CC=C4.Cl.O
Biological Activity: Metixene (Piperidine) hydrochloride hydrate is an anticholinergic and antiparkinsonian agent. Metixene hydrochloride hydrate potently inhibits binding of quinuclidinyl benzilate (QNB) with the muscarinic receptor, IC50 and Ki values of 55 nM and 15 nM, respectively. Metixene hydrochloride hydrate can be used for the research of parkinsonian[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Metixene hydrochloride hydrate | 99.92% | Metixene (Piperidine) hydrochloride hydrate is an anticholinergic and antiparkinsonian agent. Metixene hydrochloride hydrate potently inhibits binding of quinuclidinyl benzilate (QNB) with the muscarinic receptor, IC50 and Ki values of 55 nM and 15 nM, respectively. Metixene hydrochloride hydrate can be used for the research of parkinsonian. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Metixene hydrochloride hydrate (Standard) | ≥98% | Metixene (hydrochloride hydrate) (Standard) is the analytical standard of Metixene (hydrochloride hydrate). This product is intended for research and analytical applications. Metixene (Piperidine) hydrochloride hydrate is an anticholinergic and antiparkinsonian agent. Metixene hydrochloride hydrate potently inhibits binding of quinuclidinyl benzilate (QNB) with the muscarinic receptor, IC50 and Ki values of 55 nM and 15 nM, respectively. Metixene hydrochloride hydrate can be used for the research of parkinsonian. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. J. Hagenah, et al. Exogenous levodopa is not toxic to elderly subjects with non-parkinsonian movement disorders: further clinical evidence. , 106(3-4), 301–307. doi:10.1007/s007020050159
- [2]. S L Levin, et al. Dualism in the effect of cholinolytics upon the human parotid gland deprived of parasympathetic control. Int J Clin Pharmacol Res. 1986;6(5):429-39. [Content Brief]
